The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | An overview of CAR-T therapy in DLBCL and MCL
Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, comments on the key topics of a talk designed to provide oncologists and bone marrow transplant (BMT) specialists with an overview of CAR-T therapy in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The presentation recapitulated data on the three approved CAR-T products in DLBCL in the third-line setting, axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), as well as data from the three pivotal trials comparing these CAR-T therapies to standard of care (SOC) in second line in DLBCL. Advances in MCL were also highlighted and included data showing the benefits of brexucabtagene autoleucel (brexu-cel) in these patients. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Disclosures
Consultant and/or advisory board member for AbbVie, Bayer, BeiGene, BMS, Janssen, Karyopharm, Kite Pharma/Gilead, Novartis, Nurix, and Takeda. Speaker for Kite Pharma/Gilead and he has received honoraria from Novartis. Research support from BMS, Calibr, CRISPR Therapeutics, Fate Therapeutics, Kite Pharma/Gilead, MorphoSys, Novartis, Tessa Therapeutics, and Xencor.
